Item: Polynucleotides vs HA Skin Boosters (Profhilo/Skinvive)
Author: The Exosome Edit

Quick Answer

PN boosts skin quality via DNA fragments; HA boosts via water-binding gel
Profhilo = HA bioremodelling; Skinvive = FDA-cleared HA microdroplet
PN evidence is growing but smaller and shorter than HA's trial base
Most patients suit HA first; PN adds barrier and texture support

Two very different injectables get lumped into the same "skin booster" bucket, and the overlap in marketing language makes it worse. One is a fragment of purified fish DNA that asks your fibroblasts to get back to work. The other is a form of hyaluronic acid, the sugar molecule your skin already makes, injected in a pattern designed to hydrate and soften rather than fill. Both promise glow, texture, and hydration. Neither promises what a filler or a neurotoxin promises, and that's exactly where the confusion starts.

This guide breaks down polynucleotides (PN, sold as Rejuran, Plinest, Pluryal Silk, and similar brands) against the two hyaluronic acid boosters patients ask about most: Profhilo, the Italian-made HA bioremodelling injectable, and Skinvive by Juvéderm, the FDA-cleared HA microdroplet treatment. We pulled the clinical trial data for each, checked every PMID against PubMed directly, and separated what's proven from what's marketed. If a claim isn't backed by a study, we say so.

What Is a Polynucleotide (PN) Skin Booster?

Polynucleotides are short chains of purified DNA, most often extracted from salmon or trout sperm. That sounds unusual, but the manufacturing logic is simple: fish DNA is structurally close enough to human DNA that the purified fragments are recognized by human cells, while being processed down to a form with very low immunogenicity. The best-known brand is Rejuran, made by the South Korean company PharmaResearch. Other brands include Plinest, Nucleofill, and Pluryal Silk.

You'll also see the term PDRN (polydeoxyribonucleotide) used almost interchangeably with PN. In practice, PDRN generally refers to shorter, lower-molecular-weight DNA fragments — the form with the deepest pharmacology history, going back to wound-healing research on diabetic ulcers. PN usually refers to slightly longer chains marketed specifically for aesthetic skin quality. Clinics and brands blur the line constantly, so ask what's actually in the syringe rather than trusting the marketing name alone.

How does PN work on skin?

According to a 2026 international expert-consensus paper in Clinical, Cosmetic and Investigational Dermatology, PN's proposed mechanism has two main parts (Rho et al., 2026, PMID 41939258):

A2A adenosine receptor activation. PN fragments bind receptors on fibroblasts and macrophages, triggering cell proliferation, collagen synthesis, and anti-inflammatory signaling.
Hydrophilic scaffold formation. Once injected, PN forms a water-holding, gel-like matrix in the dermis that may support tissue remodeling and hydration while fibroblasts migrate through it.

Unlike hyaluronic acid, PN doesn't add meaningful physical volume. The pitch isn't "fill the line," it's "change how the tissue behaves." That's a slower, more biological process than a filler injection, and it's why PN results build gradually across a series of sessions rather than appearing immediately.

What does PN treat best?

Crepey, thin under-eye skin
Fine periorbital and perioral lines
Post-laser, post-microneedling, or post-Morpheus8 skin recovery
General dullness and loss of skin quality in early aging

Is PN, PDRN, and PNHA the same thing?

Not quite, and the terminology confusion is a real source of mismatched expectations. Here's the practical breakdown:

PDRN — the shorter, lower-molecular-weight DNA fragments, roughly 50–1,500 kDa. This is the form with the longest pharmacology track record, studied for years as a wound-healing agent before aesthetic medicine adopted it.
PN — generally longer chains, marketed for skin-boosting rather than wound repair, and often positioned by brands as "next generation."
PNHA — polynucleotide crosslinked or blended with hyaluronic acid, aiming to combine PN's regenerative signaling with HA's hydration and light structural support. The hybrid filler studied by Lee and colleagues falls into this category (PMID 41626640).

In practice, clinics and marketing copy use these terms loosely, sometimes interchangeably. If a provider tells you a product is "PN" or "PDRN," ask which specific brand and formulation it is — the molecular weight and purification process differ meaningfully between products, and most published trials study one specific brand, not the ingredient category as a whole.

What Is an HA Skin Booster?

Hyaluronic acid (HA) is a sugar molecule your body already produces to hold water in skin, joints, and connective tissue. Injectable HA boosters use very high- or low-molecular-weight HA, often lightly or non-crosslinked, delivered as a series of small intradermal deposits rather than the larger crosslinked gel used in volumizing fillers. The goal is hydration, elasticity, and glow — not shape change.

"HA booster" is not one product. It's a category, and the two most-searched names, Profhilo and Skinvive, are meaningfully different from each other. Confusing them is one of the most common mistakes patients make when booking a treatment.

Profhilo vs Skinvive: they are not the same HA booster

Profhilo is made by IBSA Farmaceutici Italia using a patented process called NAHYCO Hybrid Technology, which thermally combines high- and low-molecular-weight HA into a "hybrid cooperative complex" without chemical crosslinking agents (BDDE). It's injected at five points per side of the face (the "BAP" technique), typically as two sessions four weeks apart. Profhilo is CE-marked and sold widely across Europe, the UK, and Asia. It does not have FDA approval and is not legally available in the United States.

Skinvive by Juvéderm uses a formulation known in trials as VYC-12 — a lightly crosslinked hyaluronic acid gel delivered as microdroplet injections, typically in the cheeks. Made by Allergan Aesthetics (AbbVie), Skinvive received FDA approval on May 11, 2023, specifically for improving skin smoothness in the cheeks of adults, making it the first FDA-approved HA injectable indicated for skin quality rather than volume. It received a second FDA-cleared indication for horizontal neck lines in June 2026 (Allergan Aesthetics/AbbVie news release, 2026).

That regulatory split matters for anyone reading this in the US: if you want an HA skin booster with FDA clearance behind it, Skinvive is currently the option. Profhilo remains available through medical tourism or select international clinics, not through FDA-regulated US practices.

How does HA work as a booster (versus a filler)?

Crosslinked HA fillers are built to resist breakdown and hold physical shape — that's what makes them good at restoring volume. Booster-formulated HA is engineered differently: less or no crosslinking, lower viscosity, and placement as small superficial deposits rather than one structural bolus. The HA pulls in water and briefly increases hydration and elasticity at the injection sites, and repeated sessions are thought to stimulate the skin's own HA and collagen production over time — the "bioremodelling" claim behind Profhilo's branding specifically.

PN vs HA Skin Booster: The Comparison Table

Feature	Polynucleotides (PN/PDRN)	Profhilo (HA bioremodelling)	Skinvive by Juvéderm (HA microdroplet)
Active ingredient	Purified salmon/trout DNA fragments	Hybrid high + low MW hyaluronic acid, non-crosslinked	Lightly crosslinked hyaluronic acid (VYC-12)
Primary mechanism	A2A receptor activation + hydrophilic scaffold	Water-binding + proposed fibroblast bioremodelling	Water-binding, microdroplet hydration
Typical sessions	3–4, spaced 2–4 weeks apart	2, spaced 4 weeks apart	1, optional touch-up at ~1 month
Onset of visible change	2–4 weeks, builds over series	Days to weeks	Days to 1 month
Reported duration	~6–12 months (clinical practice reports; limited long-term trial data)	~6 months typical, per manufacturer protocol	Up to 6 months (smoothness); hydration effects reported to ~9 months in trial data
Evidence strength	Moderate: multiple small trials, one direct PN-vs-HA comparative review, strong preclinical/wound-healing base	Moderate-strong: systematic review of 9 trials (278 patients) plus large post-marketing safety data; one triple-blind RCT found mixed results	Moderate: FDA pivotal trial (n=131) plus objective digital-imaging trial (n=40)
US regulatory status	Not FDA-cleared for skin rejuvenation as of 2026	Not FDA-approved; CE-marked in EU/UK	FDA-approved (cheeks, 2023; neck, 2026)
Approx. cost per session (US)	$450–$700	Not sold in US clinics; ~~£350–£450 (~~$440–$570) per session in UK/EU	$500–$800
Best for	Barrier-compromised, crepey, or post-procedure skin; texture and fine lines	Broad skin laxity and "bioremodelling" in markets where it's approved	US patients wanting an FDA-cleared HA booster for cheek/neck smoothness

What Does the Clinical Evidence Actually Show for Polynucleotides?

The most useful summary is a 2026 narrative review in the Journal of Clinical Medicine that directly compared PN and HA fillers for under-eye rejuvenation. It concluded that "while HA remains superior for structural correction," polynucleotides "demonstrate consistent improvements in dermal quality parameters, including elasticity, hydration, and fine rhytids, with a favourable safety profile" — but flagged that heterogeneity in study design and product formulation limits firm conclusions, and called for more standardized, direct head-to-head trials (Khan & Hafeez, 2026, PMID 42452433).

Individual trials back that up, with real limitations attached:

A 2026 prospective observational study of 42 patients receiving PN injections (Pluryal Silk) for under-eye rejuvenation found statistically significant improvements in FACE-Q appraisal scores at 1, 3, and 6 months (p < 0.001), with the best results after two sessions at the 3-month mark and minimal adverse events (Ziade et al., 2026, PMID 41689167). This is a real strength — but it's observational, with no placebo or HA comparison arm, so it can't isolate how much of the benefit is PN specifically versus the injection process itself.
A small but rigorously designed exploratory RCT tested PN-HPT as a "priming" layer before crosslinked HA filler for nasolabial folds, using a split-face design against a saline placebo. The PN-primed side showed significantly better skin texture on objective 3D imaging at 6 weeks (before any HA was added) and sustained improvement through 6 months (Araco et al., 2023, PMID 35531796). It's a small trial (20 women), but it's one of the few PN studies with a genuine placebo control.
A 24-week open-label study of a hyaluronic acid-polynucleotide hybrid filler for midface volume loss found improvements in both volumetric scores and skin-quality measures (transepidermal water loss, hydration, and elasticity by Cutometer), with no serious adverse events across 15 patients (Lee et al., 2026, PMID 41626640).

The honest read: PN has real, growing clinical data, but most trials are small (12–42 patients), often industry-adjacent, and rarely placebo-controlled against a true "no treatment" arm. The expert-consensus paper backing PN's mechanism is explicit that "the current evidence base remains limited, and further studies, including randomized trials and histological validation, are needed" (Rho et al., 2026, PMID 41939258).

What Does the Clinical Evidence Show for HA Skin Boosters?

Profhilo's evidence base

A 2026 systematic review pooled nine studies covering 278 participants treated with Profhilo or Profhilo Body. It found statistically significant improvements in viscoelasticity, hydration, skin density, laxity, and Wrinkle Severity Rating Scale scores across multiple body sites (face, neck, arms, abdomen, hands), with adverse events limited to mild, expected reactions — bruising, edema, a light pinching sensation — that typically resolved within 72 hours (Sparavigna et al., 2026, PMID 41920062).

But not every rigorous trial has been as favorable. A 2026 triple-blind, split-face RCT tested Profhilo specifically for perioral wrinkles against a saline placebo in 12 women. Dermal thickness increased significantly on both the treated and placebo sides, and the improvement on the Profhilo side did not exceed the placebo effect. More than a third of participants (36.4%) reported dissatisfaction with their decision to undergo treatment, and over half (54.5%) were dissatisfied with the outcome (Zanella et al., 2026, PMID 41731228). This is exactly the kind of result marketing pages don't quote, and it's a useful reality check: Profhilo's evidence is genuinely mixed depending on body site, sample size, and how tightly the trial controls for the needle-injury effect of injection itself.

On safety, the strongest data point by far is scale, not a trial: a post-marketing surveillance analysis covering more than 1.09 million patients exposed to Profhilo's facial formulation between 2018 and 2023 recorded only 371 adverse events — 0.034% of patients — mostly edema, erythema, and discomfort consistent with the injection process (Salti et al., 2025, PMID 40654100). That's a reassuring real-world safety signal even where the efficacy picture is mixed.

Skinvive (VYC-12) evidence base

Skinvive's pivotal trial, published before FDA approval, treated 131 subjects with VYC-12 in the cheeks (and forehead/neck for some) and measured skin roughness on the Allergan Skin Roughness Scale. Responder rates were 96.2% at one month, dropping to 76.3% at four months and 34.9% at six months before a touch-up, then rebounding to 87.1% after repeat treatment. Skin hydration improved significantly through nine months (Niforos et al., 2019, PMID 31749628).

A separate trial used objective digital image analysis (not just patient or evaluator ratings) on 40 women and found skin texture improved 25.9% (± 9.2%) at day 45 and 30.7% (± 18.2%) at six months, with no major adverse events (Cavallini et al., 2019, PMID 30893167). A later retrospective analysis specifically examined delayed-onset adverse events across 2,126 VYC-12 treatments, adding to the post-market safety picture for the product (Zarbafian et al., 2022, PMID 36342258).

Head-to-head: has anyone tested PN against HA boosters directly?

Not in a large, dedicated trial — that's the honest gap in this literature. What exists are: (1) the 2026 comparative review concluding HA wins on structure while PN wins on dermal quality parameters (PMID 42452433), and (2) smaller trials using PN and HA together, sequentially or combined into hybrid fillers, rather than testing one against the other in an equivalent design (PMID 35531796, PMID 41626640). If a clinic or ad claims a head-to-head RCT proving one flatly "beats" the other for overall skin quality, that claim is currently ahead of the published evidence.

How Fast Do Results Show Up, and How Long Do They Last?

Polynucleotides

Most PN protocols run three to four sessions spaced two to four weeks apart. Visible change tends to build gradually — patients in the observational under-eye study reported the greatest improvement after two sessions, around the 3-month mark (PMID 41689167). Clinics generally report results lasting six to twelve months, but that figure comes from clinical practice and product guidance rather than long-term controlled trials, so treat it as a working estimate.

Profhilo

Profhilo's standard protocol is two sessions four weeks apart. Improvements in hydration and elasticity have been measured as early as the first weeks post-injection in the pooled systematic review data, with manufacturer guidance suggesting maintenance sessions roughly every six months (PMID 41920062). As the perioral RCT showed, results can vary substantially by treatment area and don't always outperform placebo.

Skinvive

Skinvive is designed around a single treatment, sometimes with a touch-up at 30 days to correct asymmetry. In the pivotal trial, skin-smoothness responder rates peaked at one month and declined by month six, while hydration gains persisted through nine months (PMID 31749628). The FDA label reflects this: it markets a six-month smoothness window before re-treatment is typically needed.

What Does Each Treatment Cost?

Pricing varies widely by clinic, city, and how many syringes or sessions a protocol requires, but rough US ranges look like this:

Polynucleotides (per session): $450–$700, with a full 3–4 session starter series often running $1,500–$2,600
Profhilo (not FDA-approved, not sold in standard US clinics): roughly £350–£450 (about $440–$570) per session where legally available, typically two sessions per course
Skinvive by Juvéderm (per session): $500–$800, often positioned as a single annual or biannual treatment

None of these prices are typically covered by insurance, since all three are elective cosmetic procedures. For broader context on what regenerative and quality-focused skincare procedures cost across categories, see our professional skincare treatment cost guide.

Who Is Each Treatment Best For?

Polynucleotides fit you best if:

Your skin feels thin, crepey, or "tired" rather than lined or lax
You're recovering from laser, microneedling, or another energy-device procedure and want a regenerative-leaning support treatment
You want a product with a strong wound-healing/mechanistic backstory, even though the aesthetic-specific trial base is still growing
You don't have a fish/seafood allergy history

Profhilo fits you best if:

You're being treated in a market where it's legally available (it is not FDA-approved for use in the US)
You want broad-area "bioremodelling" across face, neck, or body in two sessions
You understand the evidence is mixed by treatment site — strong systematic-review data, but at least one rigorous placebo-controlled trial showed disappointing perioral results

Skinvive fits you best if:

You're in the US and want an FDA-cleared HA option specifically studied for skin smoothness, not volume
You prefer a single-session protocol with an optional touch-up
Your main concern is cheek roughness or, per the 2026 expanded indication, horizontal neck lines

Safety and Contraindications

All three are injectable procedures and carry the general risks of any needle-based aesthetic treatment: bruising, swelling, redness, tenderness, small bumps at injection sites, and rare risks of infection or, with any filler-adjacent product, vascular occlusion if injected improperly. Choosing an experienced, licensed injector matters more than choosing a specific product.

Polynucleotide-specific note: Because PN is derived from purified fish (typically salmon or trout) DNA, anyone with a documented fish or seafood allergy should disclose this to their injector before treatment. Purified PDRN/PN carries minimal residual protein, which is why allergic reactions are uncommon, but they are not impossible, and this is a real pre-treatment screening question — not a formality.

HA-specific note: Hyaluronic acid is a naturally occurring substance in the body, and true allergic reactions are rare, though delayed inflammatory nodules have been reported with HA products generally, including in the VYC-12 delayed-adverse-event analysis (PMID 36342258).

General contraindications across all three include active skin infection at the injection site, pregnancy or breastfeeding (insufficient safety data for elective cosmetic injectables), known allergy to any product component, active autoimmune conditions affecting skin healing, and bleeding disorders or current anticoagulant therapy without physician clearance. Anyone with a history of keloid scarring or granulomatous reactions to prior fillers should discuss this explicitly before treatment.

Marketed claims to be skeptical of: "permanent" results (none of these are permanent), "replaces Botox or filler" (they work on different tissue mechanisms and don't replace muscle-relaxing or volumizing treatments), and "zero downtime, zero risk" (bruising and swelling are common and expected, even if usually mild).

One more honesty note worth flagging: a meaningful share of the trials cited above involve authors affiliated with the manufacturer (IBSA for Profhilo's post-marketing data, PharmaResearch for the PN expert-consensus paper, Allergan for the VYC-12 pivotal trial). That's common across cosmetic dermatology research generally and doesn't automatically invalidate the findings — several of these studies used independent objective measures like digital imaging, cutometry, and stereophotogrammetry rather than relying purely on patient satisfaction. But it's a reason to weight independently replicated results more heavily than any single glowing study, regardless of which product it favors.

How Should You Choose Between These at a Consultation?

Because the evidence base for all three is real but incomplete, the consultation conversation matters as much as the product choice. Questions worth asking before you book:

"What exactly is in the syringe, and what's the brand?" Generic answers like "a skin booster" or "regenerative injectable" aren't specific enough. Ask for the product name so you can look up what's actually been studied.
"How many sessions does your protocol use, and why?" A provider recommending six-plus sessions where the published protocols use two to four should explain the reasoning.
"What results have you seen in patients with my skin type and concern?" Before-and-after photos from the same clinic, not just manufacturer marketing images, are more useful.
"Is this product FDA-approved, CE-marked, or used off-label/imported here?" This is especially relevant for Profhilo and PN products in the US, where regulatory status varies and off-label or imported use shifts more of the safety burden onto the provider's sourcing practices.
"What happens if I don't like the result, and how long until we know it worked?" Given that at least one rigorous Profhilo trial found results indistinguishable from placebo in a specific treatment area (PMID 41731228), it's fair to ask a provider how they'll judge success and when.

A provider who answers these clearly and doesn't oversell "permanent" or "guaranteed" results is a better sign than any single before-and-after photo.

Frequently Asked Questions

Is a polynucleotide skin booster the same thing as Profhilo or Skinvive? No. Polynucleotides are DNA fragments; Profhilo and Skinvive are both hyaluronic acid formulations, just different HA technologies (non-crosslinked hybrid HA versus lightly crosslinked microdroplet HA). All three fall under the "skin booster" marketing umbrella, but they are chemically distinct products with different mechanisms.

Which has stronger clinical evidence, PN or HA boosters? HA has the larger and longer-running evidence base overall, including FDA pivotal trials for Skinvive and a nearly decade-long post-marketing safety dataset for Profhilo covering over a million patients. PN's evidence is real and growing but generally comes from smaller trials with shorter follow-up. A 2026 comparative review found HA superior for structural correction while PN showed more consistent dermal-quality gains — but called for more direct trials before drawing firm conclusions (PMID 42452433).

Can I combine polynucleotides with an HA skin booster? Some clinics do sequence or combine them — one exploratory trial used PN as a "priming" layer before HA filler injection and found the combination extended the HA's clinical effect (PMID 35531796), and a separate hybrid HA-PN filler product showed volumizing plus skin-quality benefits together (PMID 41626640). This is an emerging protocol, not yet backed by large trials, so treat "combo is always better" marketing claims cautiously.

Is Profhilo available in the United States? No. Profhilo is CE-marked and widely used in Europe, the UK, and parts of Asia, but it does not have FDA approval and is not legally sold through US medical practices. Skinvive by Juvéderm is the FDA-cleared HA booster option available in the US.

Do I need to worry about a fish allergy with polynucleotide injections? It's worth disclosing to your injector, yes. PN/PDRN is derived from purified salmon or trout DNA. Purified product carries very little residual protein, so reactions are uncommon, but a documented fish or seafood allergy is a legitimate screening question your provider should ask — and you should raise it even if they don't.

Sources

Khan RS, Hafeez K. Hyaluronic Acid Fillers Versus Polynucleotides for Under-Eye Rejuvenation. J Clin Med. 2026 Jun 26. PMID: 42452433. https://pubmed.ncbi.nlm.nih.gov/42452433/
Rho NK, et al. Expert Perspectives: Evidence-Based Applications of Polynucleotides (PNs) in Aesthetic Medicine and Dermatology. Clin Cosmet Investig Dermatol. 2026 Jan 14. PMID: 41939258. https://pubmed.ncbi.nlm.nih.gov/41939258/
Ziade G, et al. Prospective Observational Study of Polynucleotide Injections for Periorbital Rhytides. J Cosmet Dermatol. 2026 Feb. PMID: 41689167. https://pubmed.ncbi.nlm.nih.gov/41689167/
Araco A, Araco F, Raichi M. Clinical efficacy and safety of polynucleotides highly purified technology (PN-HPT®) and cross-linked hyaluronic acid for moderate to severe nasolabial folds: A prospective, randomized, exploratory study. J Cosmet Dermatol. 2023 Jan. PMID: 35531796. https://pubmed.ncbi.nlm.nih.gov/35531796/
Lee SY, Youn CS, Park KY. Midface volumization and skin quality enhancement with a hyaluronic acid-polynucleotide hybrid filler: a 24-week prospective open-label study. J Dermatolog Treat. 2026 Dec. PMID: 41626640. https://pubmed.ncbi.nlm.nih.gov/41626640/
Sparavigna A, et al. A Systematic Review of the Efficacy and Safety of Profhilo® and Profhilo® Body. Plast Aesthet Nurs (Phila). 2026 Apr-Jun. PMID: 41920062. https://pubmed.ncbi.nlm.nih.gov/41920062/
Zanella G, et al. Effects of Profhilo® Tissue Bioremodeling on Skin Texture and Perioral Wrinkles: A Randomized Controlled Triple-Blind Clinical Trial. Aesthetic Plast Surg. 2026 Jun. PMID: 41731228. https://pubmed.ncbi.nlm.nih.gov/41731228/
Salti G, et al. Hyaluronic Acid Hybrid Cooperative Complexes Nearing 10 Years of Use: Update on Safety Assessment Based on Post-Marketing Surveillance Data. J Cosmet Dermatol. 2025 Jul. PMID: 40654100. https://pubmed.ncbi.nlm.nih.gov/40654100/
Niforos F, et al. VYC-12 Injectable Gel Is Safe And Effective For Improvement Of Facial Skin Topography: A Prospective Study. Clin Cosmet Investig Dermatol. 2019 Oct 24. PMID: 31749628. https://pubmed.ncbi.nlm.nih.gov/31749628/
Cavallini M, et al. Skin Quality Improvement With VYC-12, a New Injectable Hyaluronic Acid: Objective Results Using Digital Analysis. Dermatol Surg. 2019 Dec. PMID: 30893167. https://pubmed.ncbi.nlm.nih.gov/30893167/
Zarbafian M, Beleznay K, Humphrey S. Delayed Adverse Events With VYC-12: A Retrospective Analysis of 2,126 Treatments. Dermatol Surg. 2022 Nov 1. PMID: 36342258. https://pubmed.ncbi.nlm.nih.gov/36342258/
Allergan Aesthetics (AbbVie). Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance. 2026 Jun 16. https://news.abbvie.com/2026-06-16-Allergan-Aesthetics-Receives-U-S-FDA-Approval-for-SKINVIVE-by-JUVEDERM-R-for-the-Improvement-of-Neck-Appearance

— The Exosome Edit Team

Polynucleotides vs HA Skin Boosters (Profhilo/Skinvive): Head-to-Head